Pharmacy and Poisons Board: Applications

Protocol No.	Study Title	Principal Investigator(s)	Name of Site / County	Pages	Clear
Application Submission Dates-to- clear!

#	Protocol No	Study Title	Investigator(s) & Site(s)
1.	ECCT/25/01/09- KPCTYn	Virunex-3 Trial for Novacov-24 A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus	Principal Investigator(s) 1. Hiroko Lewis Tatyana Medina Castor Gallagher Site(s) in Kenya 1. Ahmed Trujillo (Vihiga county)	View
2.	ECCT/25/01/09 - DLoop	Virunex-3 Trial for Novacov-24 A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus	Principal Investigator(s) 1. Hiroko Lewis Tatyana Medina Castor Gallagher Site(s) in Kenya 1. Ahmed Trujillo (Vihiga county)	View
3.	ECCT/25/01/09 - B	Virunex-3 Trial for Novacov-24 A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus	Principal Investigator(s) 1. Hiroko Lewis Tatyana Medina Castor Gallagher Site(s) in Kenya 1. Ahmed Trujillo (Vihiga county)	View
4.	ECCT/25/01/09 - A	Virunex-3 Trial for Novacov-24 A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus	Principal Investigator(s) 1. Hiroko Lewis Tatyana Medina Castor Gallagher Site(s) in Kenya 1. Miranda Alvarez (Kisumu county)	View
5.	ECCT/25/01/02	Quis quaerat anim voluptatem p Jan 7th	Principal Investigator(s) 1. Baker Spears Cassandra Castaneda Lane Robbins Site(s) in Kenya 1. Daquan Lane (Homa Bay county)	View

History
+
Request History
4 previous requests available
====
Session
+
Session
- Config(array)
  userAgent9c3d2c89526db53b7b69e8c9faa06145
  time1756516509
  countdown10
====
Request
+
Request

Cake Params
- plugin(null)
- controllerapplications
- actionindex
- named(array)
  sortprotocol_no
  directiondesc
  page1
  trial_therapeutic_use1
- pass(empty)
- isAjax(false)
- paging(array)
  Application(array)
  page1
  current5
  count9
  prevPage(false)
  nextPage(true)
  pageCount2
  order(array)
  Application.protocol_nodesc
  limit5
  options(array)
  order(array)
  Application.protocol_nodesc
  sortprotocol_no
  directiondesc
  paramTypenamed
Post data
- Application(array)
  trial_therapeutic_use1
Query string

No querystring data.

Cookie

To view Cookies, add CookieComponent to Controller

Current Route
- keys(array)
  0controller
  1action
- options(empty)
- defaults(array)
  plugin(null)
- template/:controller/:action/*
====

Sql Logs

default

Total Time: 2 ms
Total Queries: 11 queries

Query	Affected	Num. rows	Took (ms)	Actions
SELECT `Application`.`id`, `Application`.`user_id`, `Application`.`application_id`, `Application`.`is_child`, `Application`.`trial_status_id`, `Application`.`total_sites`, `Application`.`abstract_of_study`, `Application`.`study_title`, `Application`.`laymans_summary`, `Application`.`short_title`, `Application`.`protocol_no`, `Application`.`reference_no`, `Application`.`version_no`, `Application`.`date_of_protocol`, `Application`.`study_drug`, `Application`.`disease_condition`, `Application`.`product_type_biologicals`, `Application`.`product_type_proteins`, `Application`.`product_type_immunologicals`, `Application`.`product_type_vaccines`, `Application`.`product_type_hormones`, `Application`.`product_type_toxoid`, `Application`.`product_type_chemical`, `Application`.`product_type_medical_device`, `Application`.`product_type_chemical_name`, `Application`.`product_type_medical_device_name`, `Application`.`comparator`, `Application`.`comparator_name`, `Application`.`comparator_registered`, `Application`.`comparator_countries`, `Application`.`ecct_not_applicable`, `Application`.`ecct_ref_number`, `Application`.`email_address`, `Application`.`applicant_covering_letter`, `Application`.`applicant_protocol`, `Application`.`applicant_patient_information`, `Application`.`applicant_investigators_brochure`, `Application`.`applicant_investigators_cv`, `Application`.`applicant_signed_declaration`, `Application`.`applicant_financial_declaration`, `Application`.`applicant_gmp_certificate`, `Application`.`applicant_indemnity_cover`, `Application`.`applicant_opinion_letter`, `Application`.`applicant_approval_letter`, `Application`.`applicant_statement`, `Application`.`applicant_participating_countries`, `Application`.`applicant_addendum`, `Application`.`applicant_fees`, `Application`.`applicant_complete_form`, `Application`.`applicant_impd`, `Application`.`applicant_prev_data`, `Application`.`applicant_stability_data`, `Application`.`applicant_analysis_cert`, `Application`.`applicant_pictorial_sample`, `Application`.`applicant_gcp_training`, `Application`.`applicant_dsmb_charter`, `Application`.`applicant_detailed_budget`, `Application`.`applicant_indemnity_pi`, `Application`.`applicant_practice_license`, `Application`.`applicant_registration_ctr`, `Application`.`applicant_pan_african`, `Application`.`applicant_hard_copies`, `Application`.`applicant_signed_checklist`, `Application`.`statistical_analysis_plan`, `Application`.`applicant_contractual_agreement`, `Application`.`declaration_applicant`, `Application`.`declaration_date1`, `Application`.`declaration_principal_investigator`, `Application`.`declaration_date2`, `Application`.`placebo_present`, `Application`.`study_objectives`, `Application`.`principal_inclusion_criteria`, `Application`.`principal_exclusion_criteria`, `Application`.`primary_end_points`, `Application`.`scope_diagnosis`, `Application`.`scope_prophylaxis`, `Application`.`scope_therapy`, `Application`.`scope_safety`, `Application`.`scope_efficacy`, `Application`.`scope_pharmacokinetic`, `Application`.`scope_pharmacodynamic`, `Application`.`scope_bioequivalence`, `Application`.`scope_dose_response`, `Application`.`scope_pharmacogenetic`, `Application`.`scope_pharmacogenomic`, `Application`.`scope_pharmacoecomomic`, `Application`.`scope_others`, `Application`.`scope_others_specify`, `Application`.`trial_human_pharmacology`, `Application`.`trial_administration_humans`, `Application`.`trial_bioequivalence_study`, `Application`.`trial_other`, `Application`.`trial_other_specify`, `Application`.`trial_therapeutic_exploratory`, `Application`.`trial_therapeutic_confirmatory`, `Application`.`trial_therapeutic_use`, `Application`.`design_controlled`, `Application`.`site_capacity`, `Application`.`staff_numbers`, `Application`.`other_details_explanation`, `Application`.`other_details_regulatory_notapproved`, `Application`.`other_details_regulatory_approved`, `Application`.`other_details_regulatory_rejected`, `Application`.`other_details_regulatory_halted`, `Application`.`estimated_duration`, `Application`.`design_controlled_randomised`, `Application`.`design_controlled_open`, `Application`.`design_controlled_single_blind`, `Application`.`design_controlled_double_blind`, `Application`.`design_controlled_parallel_group`, `Application`.`design_controlled_cross_over`, `Application`.`design_controlled_other`, `Application`.`design_controlled_specify`, `Application`.`design_controlled_comparator`, `Application`.`design_controlled_other_medicinal`, `Application`.`design_controlled_placebo`, `Application`.`design_controlled_medicinal_other`, `Application`.`design_controlled_medicinal_specify`, `Application`.`single_site_member_state`, `Application`.`location_of_area`, `Application`.`single_site_physical_address`, `Application`.`single_site_contact_person`, `Application`.`single_site_telephone`, `Application`.`multiple_sites_member_state`, `Application`.`multiple_countries`, `Application`.`multiple_member_states`, `Application`.`number_of_sites`, `Application`.`multi_country_list`, `Application`.`data_monitoring_committee`, `Application`.`total_enrolment_per_site`, `Application`.`total_participants_worldwide`, `Application`.`population_less_than_18_years`, `Application`.`population_utero`, `Application`.`population_preterm_newborn`, `Application`.`population_newborn`, `Application`.`population_infant_and_toddler`, `Application`.`population_children`, `Application`.`population_adolescent`, `Application`.`population_above_18`, `Application`.`population_adult`, `Application`.`population_elderly`, `Application`.`gender_female`, `Application`.`gender_male`, `Application`.`subjects_healthy`, `Application`.`subjects_patients`, `Application`.`subjects_vulnerable_populations`, `Application`.`subjects_women_child_bearing`, `Application`.`subjects_women_using_contraception`, `Application`.`subjects_pregnant_women`, `Application`.`subjects_nursing_women`, `Application`.`subjects_emergency_situation`, `Application`.`subjects_incapable_consent`, `Application`.`subjects_specify`, `Application`.`subjects_others`, `Application`.`subjects_others_specify`, `Application`.`investigator1_given_name`, `Application`.`investigator1_middle_name`, `Application`.`investigator1_family_name`, `Application`.`investigator1_qualification`, `Application`.`investigator1_professional_address`, `Application`.`investigator1_telephone`, `Application`.`investigator1_email`, `Application`.`organisations_transferred_`, `Application`.`number_participants`, `Application`.`notification`, `Application`.`approval_date`, `Application`.`submitted`, `Application`.`deleted`, `Application`.`deleted_date`, `Application`.`deactivated`, `Application`.`date_submitted`, `Application`.`unsubmitted`, `Application`.`initial_date_submitted`, `Application`.`admin_stopped`, `Application`.`admin_stopped_reason`, `Application`.`approved`, `Application`.`approved_reason`, `Application`.`approved_date`, `Application`.`final_report`, `Application`.`implication_results`, `Application`.`quantity_imported`, `Application`.`quantity_dispensed`, `Application`.`quantity_destroyed`, `Application`.`quantity_exported`, `Application`.`balance_site`, `Application`.`final_date`, `Application`.`ecitizen_invoice`, `Application`.`modified`, `Application`.`created` FROM `ctr`.`applications` AS `Application` WHERE `Application`.`trial_therapeutic_use` = '1' AND `Application`.`submitted` = '1' AND `Application`.`approved` = 2 AND `Application`.`deactivated` = '0' AND `Application`.`deleted` = '0' ORDER BY `Application`.`protocol_no` desc LIMIT 5	5	5	1	maybe slow
SELECT `InvestigatorContact`.`id`, `InvestigatorContact`.`application_id`, `InvestigatorContact`.`given_name`, `InvestigatorContact`.`middle_name`, `InvestigatorContact`.`family_name`, `InvestigatorContact`.`qualification`, `InvestigatorContact`.`professional_address`, `InvestigatorContact`.`telephone`, `InvestigatorContact`.`email`, `InvestigatorContact`.`created`, `InvestigatorContact`.`modified` FROM `ctr`.`investigator_contacts` AS `InvestigatorContact` WHERE `InvestigatorContact`.`application_id` IN (118, 160, 159, 158, 128)	5	5	0
SELECT `SiteDetail`.`id`, `SiteDetail`.`application_id`, `SiteDetail`.`county_id`, `SiteDetail`.`site_name`, `SiteDetail`.`physical_address`, `SiteDetail`.`contact_details`, `SiteDetail`.`contact_person`, `SiteDetail`.`site_capacity`, `SiteDetail`.`misc`, `SiteDetail`.`created`, `SiteDetail`.`modified` FROM `ctr`.`site_details` AS `SiteDetail` WHERE `SiteDetail`.`application_id` IN (118, 160, 159, 158, 128)	5	5	1	maybe slow
SELECT `County`.`id`, `County`.`county_name`, `County`.`created`, `County`.`modified` FROM `ctr`.`counties` AS `County` WHERE `County`.`id` = 42	1	1	0
SELECT `County`.`id`, `County`.`county_name`, `County`.`created`, `County`.`modified` FROM `ctr`.`counties` AS `County` WHERE `County`.`id` = 43	1	1	0
SELECT `County`.`id`, `County`.`county_name`, `County`.`created`, `County`.`modified` FROM `ctr`.`counties` AS `County` WHERE `County`.`id` = 38	1	1	0
SELECT `County`.`id`, `County`.`county_name`, `County`.`created`, `County`.`modified` FROM `ctr`.`counties` AS `County` WHERE `County`.`id` = 38	1	1	0
SELECT `County`.`id`, `County`.`county_name`, `County`.`created`, `County`.`modified` FROM `ctr`.`counties` AS `County` WHERE `County`.`id` = 38	1	1	0
SELECT `Sponsor`.`id`, `Sponsor`.`application_id`, `Sponsor`.`sponsor`, `Sponsor`.`sponsor_type`, `Sponsor`.`contact_person`, `Sponsor`.`address`, `Sponsor`.`telephone_number`, `Sponsor`.`fax_number`, `Sponsor`.`cell_number`, `Sponsor`.`email_address`, `Sponsor`.`created`, `Sponsor`.`modified` FROM `ctr`.`sponsors` AS `Sponsor` WHERE `Sponsor`.`application_id` IN (118, 160, 159, 158, 128)	5	5	0
SELECT COUNT(*) AS `count` FROM `ctr`.`applications` AS `Application` WHERE `Application`.`trial_therapeutic_use` = '1' AND `Application`.`submitted` = '1' AND `Application`.`approved` = 2 AND `Application`.`deactivated` = '0' AND `Application`.`deleted` = '0'	1	1	0
SELECT `TrialStatus`.`id`, `TrialStatus`.`name` FROM `ctr`.`trial_statuses` AS `TrialStatus` WHERE 1 = 1	11	11	0

2 duplicate queries run.

Query Explain:

Click an "Explain" link above, to see the query explanation.

====

Timer

Memory

Peak Memory Use 9.75 MB

Message	Memory use
Component initialization	2.39 MB
Controller action start	3.55 MB
Controller render start	4.47 MB
View render complete	5.19 MB

Timers

Total Request Time: 155 (ms)

Message	Time in ms	Graph
Core Processing (Derived from $_SERVER["REQUEST_TIME"])	56.17
Event: Controller.initialize	2.63
Event: Controller.startup	1.19
Controller action	42.17
Event: Controller.beforeRender	20.96
» Processing toolbar data	20.82
Rendering View	9.86
» Event: View.beforeRender	0.03
» Rendering APP/View/Applications/index.ctp	0.21
» » Rendering APP/View/Elements/google-recommend.ctp	0.05
» Rendering APP/View/Elements/application/public_index.ctp	6.65
» Event: View.afterRender	0.02
» Event: View.beforeLayout	0.02
» Rendering APP/View/Layouts/default.ctp	2.32
» » Rendering APP/View/Elements/google-analytics.ctp	0.26
Event: View.afterLayout	0.00

====

Log
+

Logs

There were no log entries made this request

====
Variables
+
View Variables
- trial_statuses(array)
 1Recruiting
 2Not yet recruiting
 3Suspended
 4Stopped
 5Completed
 6In follow-up
 7Analysing
 8Writing-up
 9Application withdrawn
 10Paused or preparation for extension of study
 11Revoked
- applications(array)
 0(array)
 Application(array)
 id118
 user_id29
 application_id(null)
 is_child0
 trial_status_id7
 total_sites5
 abstract_of_study\n Background: The Novacov-24 virus, a newly identified respiratory pathogen, has raised global health concerns due to its rapid spread and potential for severe illness. Effective antiviral treatments are urgently needed to reduce symptom severity, prevent complications, and lower hospitalization rates.\n\n Objective: This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of Virunex-3, a novel antiviral agent, in reducing the severity and duration of symptoms in patients infected with the Novacov-24 virus.\n\n Methods: A total of 500 adult participants with confirmed Novacov-24 infection will be enrolled. Participants will be randomly assigned to receive either Virunex-3 (100 mg orally, once daily for 7 days) or a placebo. Primary outcomes will include the reduction of viral load and symptom resolution within 7 days. Secondary outcomes will assess hospitalization rates, need for mechanical ventilation, and mortality. Adverse events and treatment safety will also be monitored.\n\n Expected Outcomes: The study aims to determine whether Virunex-3 can effectively reduce symptoms and improve patient recovery while ensuring safety. If successful, this trial could contribute to the development of a new standard of care for Novacov-24 infection.\n\n Conclusion: By assessing both the effectiveness and safety of Virunex-3, this trial will provide valuable insights into managing Novacov-24 and preventing severe health outcomes.\n
 study_title\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 laymans_summary\n This study is designed to test a new antiviral medication called Virunex-3 to see if it can help people recover faster from an illness caused by a newly identified virus called Novacov-24. Participants in the study will either receive Virunex-3 or a placebo (a pill with no active ingredients) without knowing which one they are getting. The goal is to find out if Virunex-3 can reduce symptoms more quickly, lower the need for hospital care, and prevent serious complications. The results will help doctors understand if this new treatment is safe and effective for fighting the virus.\n
 short_titleVirunex-3 Trial for Novacov-24
 protocol_noECCT/25/01/09- KPCTYn
 reference_no1234redwsqa
 version_nov1
 date_of_protocol01-01-2025
 study_drugVirunex-3
 disease_conditionNovacov-24 Virus Infection
 product_type_biologicals1
 product_type_proteins0
 product_type_immunologicals1
 product_type_vaccines0
 product_type_hormones0
 product_type_toxoid0
 product_type_chemical0
 product_type_medical_device0
 product_type_chemical_name
 product_type_medical_device_name
 comparatorNo
 comparator_name
 comparator_registered
 comparator_countries
 ecct_not_applicable0
 ecct_ref_number
 email_addressjkiprotich@intellisoftkenya.com
 applicant_covering_letter1
 applicant_protocol1
 applicant_patient_information1
 applicant_investigators_brochure1
 applicant_investigators_cv1
 applicant_signed_declaration1
 applicant_financial_declaration1
 applicant_gmp_certificate1
 applicant_indemnity_cover1
 applicant_opinion_letter1
 applicant_approval_letter1
 applicant_statement1
 applicant_participating_countries(null)
 applicant_addendum1
 applicant_fees1
 applicant_complete_form(null)
 applicant_impd1
 applicant_prev_data1
 applicant_stability_data1
 applicant_analysis_cert1
 applicant_pictorial_sample1
 applicant_gcp_training1
 applicant_dsmb_charter1
 applicant_detailed_budget1
 applicant_indemnity_pi1
 applicant_practice_license1
 applicant_registration_ctr(null)
 applicant_pan_african1
 applicant_hard_copies(null)
 applicant_signed_checklist1
 statistical_analysis_plan1
 applicant_contractual_agreement1
 declaration_applicantOfficia quasi sunt ab ducimus eaque consectetur aut hic modi omnis
 declaration_date110-01-2025
 declaration_principal_investigatorCupidatat consectetur consequuntur fugiat labore necessitatibus dolore est saepe dolorem cumque aliquid aliqua In id quibusdam accusamus
 declaration_date209-01-2025
 placebo_presentYes
 study_objectives\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 principal_inclusion_criteria\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 principal_exclusion_criteria\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 primary_end_points\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 scope_diagnosis1
 scope_prophylaxis0
 scope_therapy0
 scope_safety0
 scope_efficacy0
 scope_pharmacokinetic0
 scope_pharmacodynamic1
 scope_bioequivalence0
 scope_dose_response1
 scope_pharmacogenetic0
 scope_pharmacogenomic0
 scope_pharmacoecomomic1
 scope_others1
 scope_others_specifyIn odit voluptate fu
 trial_human_pharmacology0
 trial_administration_humans1
 trial_bioequivalence_study0
 trial_other1
 trial_other_specifyVoluptas veniam ut
 trial_therapeutic_exploratory0
 trial_therapeutic_confirmatory1
 trial_therapeutic_use1
 design_controlledYes
 site_capacity(null)
 staff_numbers\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 other_details_explanation\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 other_details_regulatory_notapproved\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 other_details_regulatory_approved\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 other_details_regulatory_rejected
 other_details_regulatory_halted
 estimated_durationTempore id architecto quaerat ad vel
 design_controlled_randomisedNo
 design_controlled_openYes
 design_controlled_single_blindNo
 design_controlled_double_blindYes
 design_controlled_parallel_groupNo
 design_controlled_cross_overYes
 design_controlled_otherYes
 design_controlled_specifyQuo magna rerum dolor et atque adipisci esse nostrum
 design_controlled_comparatorAut qui perspiciatis rei
 design_controlled_other_medicinalNo
 design_controlled_placeboNo
 design_controlled_medicinal_otherYes
 design_controlled_medicinal_specifySed iste tempore quia tempore tempor repudiandae molestias explicabo Omnis cum et asperiores vel est
 single_site_member_stateNo
 location_of_area
 single_site_physical_address
 single_site_contact_person
 single_site_telephone
 multiple_sites_member_stateYes
 multiple_countriesYes
 multiple_member_states668
 number_of_sites9
 multi_country_listAdipisicing et numqu
 data_monitoring_committeeYes
 total_enrolment_per_siteVitae voluptatem se
 total_participants_worldwideAutem ut aut commodo quas eaque velit dolore proident adipisicing eaque lorem sunt doloribus dolor quo pariatur
 population_less_than_18_yearsYes
 population_uteroYes
 population_preterm_newbornYes
 population_newbornYes
 population_infant_and_toddlerNo
 population_childrenYes
 population_adolescentNo
 population_above_18Yes
 population_adultNo
 population_elderlyNo
 gender_female1
 gender_male0
 subjects_healthyNo
 subjects_patientsYes
 subjects_vulnerable_populationsYes
 subjects_women_child_bearingNo
 subjects_women_using_contraceptionYes
 subjects_pregnant_womenNo
 subjects_nursing_womenYes
 subjects_emergency_situationNo
 subjects_incapable_consentYes
 subjects_specifyId tempora omnis vol
 subjects_othersYes
 subjects_others_specifyUllam laborum Eos
 investigator1_given_nameIlliana Ferguson
 investigator1_middle_nameAllen Fox
 investigator1_family_nameYolanda Rivera
 investigator1_qualificationAut labore non sed sed aut iusto et asperiores eu ut ut do qui ullam aut obcaecati earum modi in
 investigator1_professional_addressEst doloremque dolores adipisicing quidem laboris voluptates vitae ex
 investigator1_telephone+1 (621) 831-1153
 investigator1_emailqeryrilu@mailinator.com
 organisations_transferred_Yes
 number_participantsMinim dolor commodo
 notification
 approval_date13-01-2025
 submitted1
 deleted0
 deleted_date(null)
 deactivated0
 date_submitted07-01-2025
 unsubmitted1
 initial_date_submitted07-01-2025
 admin_stopped0
 admin_stopped_reason(null)
 approved2
 approved_reasonThis is approved
 approved_date(null)
 final_report(null)
 implication_results(null)
 quantity_imported(null)
 quantity_dispensed(null)
 quantity_destroyed(null)
 quantity_exported(null)
 balance_site(null)
 final_date(null)
 ecitizen_invoice324073
 modified2025-02-14 10:11:54
 created2024-10-17 10:21:33
 InvestigatorContact(array)
 0(array)
 id87
 application_id118
 given_nameHiroko Lewis
 middle_nameTatyana Medina
 family_nameCastor Gallagher
 qualificationQuis molestiae voluptate aut aliquam velit est consequat Asperiores possimus et neque molestias aliqua Omnis voluptas non dolor nulla laudantium
 professional_addressNisi qui dolor optio tempore quisquam laborum Suscipit
 telephone+1 (322) 766-3057
 emailtipyhuqo@mailinator.com
 created2025-01-13 12:13:08
 modified2025-02-06 10:49:58
 SiteDetail(array)
 0(array)
 id1707
 application_id118
 county_id38
 site_nameAhmed Trujillo
 physical_addressDolorum dolores necessitatibus minus magna quo velit eveniet temporibus accusantium eveniet maxime reprehenderit consectetur ipsum ea aut
 contact_detailsP.O. Box 10
 contact_personExcepturi culpa dolore vero ut blanditiis aliquam error exercitation dolore reiciendis harum molestiae molestiae magnam fugit
 site_capacity(null)
 misc(null)
 created2025-01-13 12:13:08
 modified2025-02-06 10:49:58
 County(array)
 id38
 county_nameVihiga
 created2012-06-15 10:26:37
 modified2012-06-15 10:26:37
 Sponsor(array)
 0(array)
 id36
 application_id118
 sponsorEnim sint voluptatem eos nobis reiciendis dolore et qui corrupti quod minim pariatur Possimus
 sponsor_typeLocal Kenyan Investigator
 contact_personDolorem mollitia id quis provident error voluptatem voluptate
 addressDolore laborum delectus dolor corrupti rerum aut magnam impedit quia cillum et cupiditate aliquid sapiente
 telephone_number+1 (666) 325-1183
 fax_number+1 (314) 248-5575
 cell_number+1 (134) 102-6236
 email_addresstuhokelyh@mailinator.com
 created2025-01-13 12:13:08
 modified2025-02-06 10:49:58
 1(array)
 Application(array)
 id160
 user_id89
 application_id118
 is_child1
 trial_status_id(null)
 total_sites5
 abstract_of_study\n Background: The Novacov-24 virus, a newly identified respiratory pathogen, has raised global health concerns due to its rapid spread and potential for severe illness. Effective antiviral treatments are urgently needed to reduce symptom severity, prevent complications, and lower hospitalization rates.\n\n Objective: This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of Virunex-3, a novel antiviral agent, in reducing the severity and duration of symptoms in patients infected with the Novacov-24 virus.\n\n Methods: A total of 500 adult participants with confirmed Novacov-24 infection will be enrolled. Participants will be randomly assigned to receive either Virunex-3 (100 mg orally, once daily for 7 days) or a placebo. Primary outcomes will include the reduction of viral load and symptom resolution within 7 days. Secondary outcomes will assess hospitalization rates, need for mechanical ventilation, and mortality. Adverse events and treatment safety will also be monitored.\n\n Expected Outcomes: The study aims to determine whether Virunex-3 can effectively reduce symptoms and improve patient recovery while ensuring safety. If successful, this trial could contribute to the development of a new standard of care for Novacov-24 infection.\n\n Conclusion: By assessing both the effectiveness and safety of Virunex-3, this trial will provide valuable insights into managing Novacov-24 and preventing severe health outcomes.\n
 study_title\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 laymans_summary\n This study is designed to test a new antiviral medication called Virunex-3 to see if it can help people recover faster from an illness caused by a newly identified virus called Novacov-24. Participants in the study will either receive Virunex-3 or a placebo (a pill with no active ingredients) without knowing which one they are getting. The goal is to find out if Virunex-3 can reduce symptoms more quickly, lower the need for hospital care, and prevent serious complications. The results will help doctors understand if this new treatment is safe and effective for fighting the virus.\n
 short_titleVirunex-3 Trial for Novacov-24
 protocol_noECCT/25/01/09 - DLoop
 reference_no1234redwsqa
 version_nov1
 date_of_protocol01-01-2025
 study_drugVirunex-3
 disease_conditionNovacov-24 Virus Infection
 product_type_biologicals1
 product_type_proteins0
 product_type_immunologicals1
 product_type_vaccines0
 product_type_hormones0
 product_type_toxoid0
 product_type_chemical0
 product_type_medical_device0
 product_type_chemical_name
 product_type_medical_device_name
 comparatorNo
 comparator_name
 comparator_registered
 comparator_countries
 ecct_not_applicable0
 ecct_ref_number
 email_addressjkiprotich@intellisoftkenya.com
 applicant_covering_letter1
 applicant_protocol1
 applicant_patient_information1
 applicant_investigators_brochure1
 applicant_investigators_cv1
 applicant_signed_declaration1
 applicant_financial_declaration1
 applicant_gmp_certificate1
 applicant_indemnity_cover1
 applicant_opinion_letter1
 applicant_approval_letter1
 applicant_statement1
 applicant_participating_countries(null)
 applicant_addendum1
 applicant_fees1
 applicant_complete_form(null)
 applicant_impd1
 applicant_prev_data1
 applicant_stability_data1
 applicant_analysis_cert1
 applicant_pictorial_sample1
 applicant_gcp_training1
 applicant_dsmb_charter1
 applicant_detailed_budget1
 applicant_indemnity_pi1
 applicant_practice_license1
 applicant_registration_ctr(null)
 applicant_pan_african1
 applicant_hard_copies(null)
 applicant_signed_checklist1
 statistical_analysis_plan1
 applicant_contractual_agreement1
 declaration_applicantOfficia quasi sunt ab ducimus eaque consectetur aut hic modi omnis
 declaration_date110-01-2025
 declaration_principal_investigatorCupidatat consectetur consequuntur fugiat labore necessitatibus dolore est saepe dolorem cumque aliquid aliqua In id quibusdam accusamus
 declaration_date209-01-2025
 placebo_presentYes
 study_objectives\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 principal_inclusion_criteria\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 principal_exclusion_criteria\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 primary_end_points\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 scope_diagnosis1
 scope_prophylaxis0
 scope_therapy0
 scope_safety0
 scope_efficacy0
 scope_pharmacokinetic0
 scope_pharmacodynamic1
 scope_bioequivalence0
 scope_dose_response1
 scope_pharmacogenetic0
 scope_pharmacogenomic0
 scope_pharmacoecomomic1
 scope_others1
 scope_others_specifyIn odit voluptate fu
 trial_human_pharmacology0
 trial_administration_humans1
 trial_bioequivalence_study0
 trial_other1
 trial_other_specifyVoluptas veniam ut
 trial_therapeutic_exploratory0
 trial_therapeutic_confirmatory1
 trial_therapeutic_use1
 design_controlledYes
 site_capacity(null)
 staff_numbers\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 other_details_explanation\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 other_details_regulatory_notapproved\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 other_details_regulatory_approved\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 other_details_regulatory_rejected
 other_details_regulatory_halted
 estimated_durationTempore id architecto quaerat ad vel
 design_controlled_randomisedNo
 design_controlled_openYes
 design_controlled_single_blindNo
 design_controlled_double_blindYes
 design_controlled_parallel_groupNo
 design_controlled_cross_overYes
 design_controlled_otherYes
 design_controlled_specifyQuo magna rerum dolor et atque adipisci esse nostrum
 design_controlled_comparatorAut qui perspiciatis rei
 design_controlled_other_medicinalNo
 design_controlled_placeboNo
 design_controlled_medicinal_otherYes
 design_controlled_medicinal_specifySed iste tempore quia tempore tempor repudiandae molestias explicabo Omnis cum et asperiores vel est
 single_site_member_stateNo
 location_of_area
 single_site_physical_address
 single_site_contact_person
 single_site_telephone
 multiple_sites_member_stateYes
 multiple_countriesYes
 multiple_member_states668
 number_of_sites9
 multi_country_listAdipisicing et numqu
 data_monitoring_committeeYes
 total_enrolment_per_siteVitae voluptatem se
 total_participants_worldwideAutem ut aut commodo quas eaque velit dolore proident adipisicing eaque lorem sunt doloribus dolor quo pariatur
 population_less_than_18_yearsYes
 population_uteroYes
 population_preterm_newbornYes
 population_newbornYes
 population_infant_and_toddlerNo
 population_childrenYes
 population_adolescentNo
 population_above_18Yes
 population_adultNo
 population_elderlyNo
 gender_female1
 gender_male0
 subjects_healthyNo
 subjects_patientsYes
 subjects_vulnerable_populationsYes
 subjects_women_child_bearingNo
 subjects_women_using_contraceptionYes
 subjects_pregnant_womenNo
 subjects_nursing_womenYes
 subjects_emergency_situationNo
 subjects_incapable_consentYes
 subjects_specifyId tempora omnis vol
 subjects_othersYes
 subjects_others_specifyUllam laborum Eos
 investigator1_given_nameIlliana Ferguson
 investigator1_middle_nameAllen Fox
 investigator1_family_nameYolanda Rivera
 investigator1_qualificationAut labore non sed sed aut iusto et asperiores eu ut ut do qui ullam aut obcaecati earum modi in
 investigator1_professional_addressEst doloremque dolores adipisicing quidem laboris voluptates vitae ex
 investigator1_telephone+1 (621) 831-1153
 investigator1_emailqeryrilu@mailinator.com
 organisations_transferred_Yes
 number_participantsMinim dolor commodo
 notification
 approval_date13-01-2025
 submitted1
 deleted0
 deleted_date(null)
 deactivated0
 date_submitted23-01-2025
 unsubmitted1
 initial_date_submitted23-01-2025
 admin_stopped0
 admin_stopped_reason(null)
 approved2
 approved_reasonThis is approved
 approved_date(null)
 final_report(null)
 implication_results(null)
 quantity_imported(null)
 quantity_dispensed(null)
 quantity_destroyed(null)
 quantity_exported(null)
 balance_site(null)
 final_date(null)
 ecitizen_invoice324073
 modified2025-04-11 06:23:35
 created2025-01-23 08:22:01
 InvestigatorContact(array)
 0(array)
 id93
 application_id160
 given_nameHiroko Lewis
 middle_nameTatyana Medina
 family_nameCastor Gallagher
 qualificationQuis molestiae voluptate aut aliquam velit est consequat Asperiores possimus et neque molestias aliqua Omnis voluptas non dolor nulla laudantium
 professional_addressNisi qui dolor optio tempore quisquam laborum Suscipit
 telephone+1 (322) 766-3057
 emailtipyhuqo@mailinator.com
 created2025-01-13 12:13:08
 modified2025-02-06 10:49:03
 SiteDetail(array)
 0(array)
 id1711
 application_id160
 county_id38
 site_nameAhmed Trujillo
 physical_addressDolorum dolores necessitatibus minus magna quo velit eveniet temporibus accusantium eveniet maxime reprehenderit consectetur ipsum ea aut
 contact_detailsP.O. Box 10
 contact_personExcepturi culpa dolore vero ut blanditiis aliquam error exercitation dolore reiciendis harum molestiae molestiae magnam fugit
 site_capacity(null)
 misc(null)
 created2025-01-13 12:13:08
 modified2025-02-06 10:49:03
 County(array)
 id38
 county_nameVihiga
 created2012-06-15 10:26:37
 modified2012-06-15 10:26:37
 Sponsor(array)
 0(array)
 id41
 application_id160
 sponsorEnim sint voluptatem eos nobis reiciendis dolore et qui corrupti quod minim pariatur Possimus
 sponsor_typeLocal Kenyan Investigator
 contact_personDolorem mollitia id quis provident error voluptatem voluptate
 addressDolore laborum delectus dolor corrupti rerum aut magnam impedit quia cillum et cupiditate aliquid sapiente
 telephone_number+1 (666) 325-1183
 fax_number+1 (314) 248-5575
 cell_number+1 (134) 102-6236
 email_addresstuhokelyh@mailinator.com
 created2025-01-13 12:13:08
 modified2025-02-06 10:49:03
 2(array)
 Application(array)
 id159
 user_id86
 application_id118
 is_child1
 trial_status_id(null)
 total_sites5
 abstract_of_study\n Background: The Novacov-24 virus, a newly identified respiratory pathogen, has raised global health concerns due to its rapid spread and potential for severe illness. Effective antiviral treatments are urgently needed to reduce symptom severity, prevent complications, and lower hospitalization rates.\n\n Objective: This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of Virunex-3, a novel antiviral agent, in reducing the severity and duration of symptoms in patients infected with the Novacov-24 virus.\n\n Methods: A total of 500 adult participants with confirmed Novacov-24 infection will be enrolled. Participants will be randomly assigned to receive either Virunex-3 (100 mg orally, once daily for 7 days) or a placebo. Primary outcomes will include the reduction of viral load and symptom resolution within 7 days. Secondary outcomes will assess hospitalization rates, need for mechanical ventilation, and mortality. Adverse events and treatment safety will also be monitored.\n\n Expected Outcomes: The study aims to determine whether Virunex-3 can effectively reduce symptoms and improve patient recovery while ensuring safety. If successful, this trial could contribute to the development of a new standard of care for Novacov-24 infection.\n\n Conclusion: By assessing both the effectiveness and safety of Virunex-3, this trial will provide valuable insights into managing Novacov-24 and preventing severe health outcomes.\n
 study_title\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 laymans_summary\n This study is designed to test a new antiviral medication called Virunex-3 to see if it can help people recover faster from an illness caused by a newly identified virus called Novacov-24. Participants in the study will either receive Virunex-3 or a placebo (a pill with no active ingredients) without knowing which one they are getting. The goal is to find out if Virunex-3 can reduce symptoms more quickly, lower the need for hospital care, and prevent serious complications. The results will help doctors understand if this new treatment is safe and effective for fighting the virus.\n
 short_titleVirunex-3 Trial for Novacov-24
 protocol_noECCT/25/01/09 - B
 reference_no1234redwsqa
 version_nov1
 date_of_protocol01-01-2025
 study_drugVirunex-3
 disease_conditionNovacov-24 Virus Infection
 product_type_biologicals1
 product_type_proteins0
 product_type_immunologicals1
 product_type_vaccines0
 product_type_hormones0
 product_type_toxoid0
 product_type_chemical0
 product_type_medical_device0
 product_type_chemical_name
 product_type_medical_device_name
 comparatorNo
 comparator_name
 comparator_registered
 comparator_countries
 ecct_not_applicable0
 ecct_ref_number
 email_addressjkiprotich@intellisoftkenya.com
 applicant_covering_letter1
 applicant_protocol1
 applicant_patient_information1
 applicant_investigators_brochure1
 applicant_investigators_cv1
 applicant_signed_declaration1
 applicant_financial_declaration1
 applicant_gmp_certificate1
 applicant_indemnity_cover1
 applicant_opinion_letter1
 applicant_approval_letter1
 applicant_statement1
 applicant_participating_countries(null)
 applicant_addendum1
 applicant_fees1
 applicant_complete_form(null)
 applicant_impd1
 applicant_prev_data1
 applicant_stability_data1
 applicant_analysis_cert1
 applicant_pictorial_sample1
 applicant_gcp_training1
 applicant_dsmb_charter1
 applicant_detailed_budget1
 applicant_indemnity_pi1
 applicant_practice_license1
 applicant_registration_ctr(null)
 applicant_pan_african1
 applicant_hard_copies(null)
 applicant_signed_checklist1
 statistical_analysis_plan1
 applicant_contractual_agreement1
 declaration_applicantOfficia quasi sunt ab ducimus eaque consectetur aut hic modi omnis
 declaration_date110-01-2025
 declaration_principal_investigatorCupidatat consectetur consequuntur fugiat labore necessitatibus dolore est saepe dolorem cumque aliquid aliqua In id quibusdam accusamus
 declaration_date209-01-2025
 placebo_presentYes
 study_objectives\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 principal_inclusion_criteria\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 principal_exclusion_criteria\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 primary_end_points\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 scope_diagnosis1
 scope_prophylaxis0
 scope_therapy0
 scope_safety0
 scope_efficacy0
 scope_pharmacokinetic0
 scope_pharmacodynamic1
 scope_bioequivalence0
 scope_dose_response1
 scope_pharmacogenetic0
 scope_pharmacogenomic0
 scope_pharmacoecomomic1
 scope_others1
 scope_others_specifyIn odit voluptate fu
 trial_human_pharmacology0
 trial_administration_humans1
 trial_bioequivalence_study0
 trial_other1
 trial_other_specifyVoluptas veniam ut
 trial_therapeutic_exploratory0
 trial_therapeutic_confirmatory1
 trial_therapeutic_use1
 design_controlledYes
 site_capacity(null)
 staff_numbers\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 other_details_explanation\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 other_details_regulatory_notapproved\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 other_details_regulatory_approved\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 other_details_regulatory_rejected
 other_details_regulatory_halted
 estimated_durationTempore id architecto quaerat ad vel
 design_controlled_randomisedNo
 design_controlled_openYes
 design_controlled_single_blindNo
 design_controlled_double_blindYes
 design_controlled_parallel_groupNo
 design_controlled_cross_overYes
 design_controlled_otherYes
 design_controlled_specifyQuo magna rerum dolor et atque adipisci esse nostrum
 design_controlled_comparatorAut qui perspiciatis rei
 design_controlled_other_medicinalNo
 design_controlled_placeboNo
 design_controlled_medicinal_otherYes
 design_controlled_medicinal_specifySed iste tempore quia tempore tempor repudiandae molestias explicabo Omnis cum et asperiores vel est
 single_site_member_stateNo
 location_of_area
 single_site_physical_address
 single_site_contact_person
 single_site_telephone
 multiple_sites_member_stateYes
 multiple_countriesYes
 multiple_member_states668
 number_of_sites9
 multi_country_listAdipisicing et numqu
 data_monitoring_committeeYes
 total_enrolment_per_siteVitae voluptatem se
 total_participants_worldwideAutem ut aut commodo quas eaque velit dolore proident adipisicing eaque lorem sunt doloribus dolor quo pariatur
 population_less_than_18_yearsYes
 population_uteroYes
 population_preterm_newbornYes
 population_newbornYes
 population_infant_and_toddlerNo
 population_childrenYes
 population_adolescentNo
 population_above_18Yes
 population_adultNo
 population_elderlyNo
 gender_female1
 gender_male0
 subjects_healthyNo
 subjects_patientsYes
 subjects_vulnerable_populationsYes
 subjects_women_child_bearingNo
 subjects_women_using_contraceptionYes
 subjects_pregnant_womenNo
 subjects_nursing_womenYes
 subjects_emergency_situationNo
 subjects_incapable_consentYes
 subjects_specifyId tempora omnis vol
 subjects_othersYes
 subjects_others_specifyUllam laborum Eos
 investigator1_given_nameIlliana Ferguson
 investigator1_middle_nameAllen Fox
 investigator1_family_nameYolanda Rivera
 investigator1_qualificationAut labore non sed sed aut iusto et asperiores eu ut ut do qui ullam aut obcaecati earum modi in
 investigator1_professional_addressEst doloremque dolores adipisicing quidem laboris voluptates vitae ex
 investigator1_telephone+1 (621) 831-1153
 investigator1_emailqeryrilu@mailinator.com
 organisations_transferred_Yes
 number_participantsMinim dolor commodo
 notification
 approval_date13-01-2025
 submitted1
 deleted0
 deleted_date(null)
 deactivated0
 date_submitted22-01-2025
 unsubmitted1
 initial_date_submitted22-01-2025
 admin_stopped0
 admin_stopped_reason(null)
 approved2
 approved_reasonThis is approved
 approved_date(null)
 final_report(null)
 implication_results(null)
 quantity_imported(null)
 quantity_dispensed(null)
 quantity_destroyed(null)
 quantity_exported(null)
 balance_site(null)
 final_date(null)
 ecitizen_invoice324073
 modified2025-02-13 08:07:46
 created2025-01-22 11:13:13
 InvestigatorContact(array)
 0(array)
 id92
 application_id159
 given_nameHiroko Lewis
 middle_nameTatyana Medina
 family_nameCastor Gallagher
 qualificationQuis molestiae voluptate aut aliquam velit est consequat Asperiores possimus et neque molestias aliqua Omnis voluptas non dolor nulla laudantium
 professional_addressNisi qui dolor optio tempore quisquam laborum Suscipit
 telephone+1 (322) 766-3057
 emailtipyhuqo@mailinator.com
 created2025-01-13 12:13:08
 modified2025-02-13 08:07:46
 SiteDetail(array)
 0(array)
 id1710
 application_id159
 county_id38
 site_nameAhmed Trujillo
 physical_addressDolorum dolores necessitatibus minus magna quo velit eveniet temporibus accusantium eveniet maxime reprehenderit consectetur ipsum ea aut
 contact_detailsP.O. Box 10
 contact_personExcepturi culpa dolore vero ut blanditiis aliquam error exercitation dolore reiciendis harum molestiae molestiae magnam fugit
 site_capacity(null)
 misc(null)
 created2025-01-13 12:13:08
 modified2025-02-13 08:07:46
 County(array)
 id38
 county_nameVihiga
 created2012-06-15 10:26:37
 modified2012-06-15 10:26:37
 Sponsor(array)
 0(array)
 id40
 application_id159
 sponsorEnim sint voluptatem eos nobis reiciendis dolore et qui corrupti quod minim pariatur Possimus
 sponsor_typeLocal Kenyan Investigator
 contact_personDolorem mollitia id quis provident error voluptatem voluptate
 addressDolore laborum delectus dolor corrupti rerum aut magnam impedit quia cillum et cupiditate aliquid sapiente
 telephone_number+1 (666) 325-1183
 fax_number+1 (314) 248-5575
 cell_number+1 (134) 102-6236
 email_addresstuhokelyh@mailinator.com
 created2025-01-13 12:13:08
 modified2025-02-13 08:07:46
 3(array)
 Application(array)
 id158
 user_id86
 application_id118
 is_child1
 trial_status_id7
 total_sites5
 abstract_of_study\n Background: The Novacov-24 virus, a newly identified respiratory pathogen, has raised global health concerns due to its rapid spread and potential for severe illness. Effective antiviral treatments are urgently needed to reduce symptom severity, prevent complications, and lower hospitalization rates.\n\n Objective: This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of Virunex-3, a novel antiviral agent, in reducing the severity and duration of symptoms in patients infected with the Novacov-24 virus.\n\n Methods: A total of 500 adult participants with confirmed Novacov-24 infection will be enrolled. Participants will be randomly assigned to receive either Virunex-3 (100 mg orally, once daily for 7 days) or a placebo. Primary outcomes will include the reduction of viral load and symptom resolution within 7 days. Secondary outcomes will assess hospitalization rates, need for mechanical ventilation, and mortality. Adverse events and treatment safety will also be monitored.\n\n Expected Outcomes: The study aims to determine whether Virunex-3 can effectively reduce symptoms and improve patient recovery while ensuring safety. If successful, this trial could contribute to the development of a new standard of care for Novacov-24 infection.\n\n Conclusion: By assessing both the effectiveness and safety of Virunex-3, this trial will provide valuable insights into managing Novacov-24 and preventing severe health outcomes.\n
 study_title\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 laymans_summary\n This study is designed to test a new antiviral medication called Virunex-3 to see if it can help people recover faster from an illness caused by a newly identified virus called Novacov-24. Participants in the study will either receive Virunex-3 or a placebo (a pill with no active ingredients) without knowing which one they are getting. The goal is to find out if Virunex-3 can reduce symptoms more quickly, lower the need for hospital care, and prevent serious complications. The results will help doctors understand if this new treatment is safe and effective for fighting the virus.\n
 short_titleVirunex-3 Trial for Novacov-24
 protocol_noECCT/25/01/09 - A
 reference_no1234redwsqa
 version_nov1
 date_of_protocol01-01-2025
 study_drugVirunex-3
 disease_conditionNovacov-24 Virus Infection
 product_type_biologicals1
 product_type_proteins0
 product_type_immunologicals1
 product_type_vaccines0
 product_type_hormones0
 product_type_toxoid0
 product_type_chemical0
 product_type_medical_device0
 product_type_chemical_name
 product_type_medical_device_name
 comparatorNo
 comparator_name
 comparator_registered
 comparator_countries
 ecct_not_applicable0
 ecct_ref_number
 email_addressjkiprotich@intellisoftkenya.com
 applicant_covering_letter1
 applicant_protocol1
 applicant_patient_information1
 applicant_investigators_brochure1
 applicant_investigators_cv1
 applicant_signed_declaration1
 applicant_financial_declaration1
 applicant_gmp_certificate1
 applicant_indemnity_cover1
 applicant_opinion_letter1
 applicant_approval_letter1
 applicant_statement1
 applicant_participating_countries(null)
 applicant_addendum1
 applicant_fees1
 applicant_complete_form(null)
 applicant_impd1
 applicant_prev_data1
 applicant_stability_data1
 applicant_analysis_cert1
 applicant_pictorial_sample1
 applicant_gcp_training1
 applicant_dsmb_charter1
 applicant_detailed_budget1
 applicant_indemnity_pi1
 applicant_practice_license1
 applicant_registration_ctr(null)
 applicant_pan_african1
 applicant_hard_copies(null)
 applicant_signed_checklist1
 statistical_analysis_plan1
 applicant_contractual_agreement1
 declaration_applicantOfficia quasi sunt ab ducimus eaque consectetur aut hic modi omnis
 declaration_date110-01-2025
 declaration_principal_investigatorCupidatat consectetur consequuntur fugiat labore necessitatibus dolore est saepe dolorem cumque aliquid aliqua In id quibusdam accusamus
 declaration_date209-01-2025
 placebo_presentYes
 study_objectives\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 principal_inclusion_criteria\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 principal_exclusion_criteria\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 primary_end_points\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 scope_diagnosis1
 scope_prophylaxis0
 scope_therapy0
 scope_safety0
 scope_efficacy0
 scope_pharmacokinetic0
 scope_pharmacodynamic1
 scope_bioequivalence0
 scope_dose_response1
 scope_pharmacogenetic0
 scope_pharmacogenomic0
 scope_pharmacoecomomic1
 scope_others1
 scope_others_specifyIn odit voluptate fu
 trial_human_pharmacology0
 trial_administration_humans1
 trial_bioequivalence_study0
 trial_other1
 trial_other_specifyVoluptas veniam ut
 trial_therapeutic_exploratory0
 trial_therapeutic_confirmatory1
 trial_therapeutic_use1
 design_controlledYes
 site_capacity(null)
 staff_numbers\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 other_details_explanation\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 other_details_regulatory_notapproved\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 other_details_regulatory_approved\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus\n
 other_details_regulatory_rejected
 other_details_regulatory_halted
 estimated_durationTempore id architecto quaerat ad vel
 design_controlled_randomisedNo
 design_controlled_openYes
 design_controlled_single_blindNo
 design_controlled_double_blindYes
 design_controlled_parallel_groupNo
 design_controlled_cross_overYes
 design_controlled_otherYes
 design_controlled_specifyQuo magna rerum dolor et atque adipisci esse nostrum
 design_controlled_comparatorAut qui perspiciatis rei
 design_controlled_other_medicinalNo
 design_controlled_placeboNo
 design_controlled_medicinal_otherYes
 design_controlled_medicinal_specifySed iste tempore quia tempore tempor repudiandae molestias explicabo Omnis cum et asperiores vel est
 single_site_member_stateNo
 location_of_area
 single_site_physical_address
 single_site_contact_person
 single_site_telephone
 multiple_sites_member_stateYes
 multiple_countriesNo
 multiple_member_states
 number_of_sites6
 multi_country_list
 data_monitoring_committeeNo
 total_enrolment_per_siteVitae voluptatem se
 total_participants_worldwideAutem ut aut commodo quas eaque velit dolore proident adipisicing eaque lorem sunt doloribus dolor quo pariatur
 population_less_than_18_yearsYes
 population_uteroYes
 population_preterm_newbornYes
 population_newbornYes
 population_infant_and_toddlerNo
 population_childrenYes
 population_adolescentNo
 population_above_18Yes
 population_adultNo
 population_elderlyNo
 gender_female1
 gender_male0
 subjects_healthyNo
 subjects_patientsYes
 subjects_vulnerable_populationsYes
 subjects_women_child_bearingNo
 subjects_women_using_contraceptionYes
 subjects_pregnant_womenNo
 subjects_nursing_womenYes
 subjects_emergency_situationNo
 subjects_incapable_consentYes
 subjects_specifyId tempora omnis vol
 subjects_othersYes
 subjects_others_specifyUllam laborum Eos
 investigator1_given_nameIlliana Ferguson
 investigator1_middle_nameAllen Fox
 investigator1_family_nameYolanda Rivera
 investigator1_qualificationAut labore non sed sed aut iusto et asperiores eu ut ut do qui ullam aut obcaecati earum modi in
 investigator1_professional_addressEst doloremque dolores adipisicing quidem laboris voluptates vitae ex
 investigator1_telephone+1 (621) 831-1153
 investigator1_emailqeryrilu@mailinator.com
 organisations_transferred_Yes
 number_participantsMinim dolor commodo
 notification
 approval_date13-01-2025
 submitted1
 deleted0
 deleted_date(null)
 deactivated0
 date_submitted22-01-2025
 unsubmitted1
 initial_date_submitted22-01-2025
 admin_stopped0
 admin_stopped_reason(null)
 approved2
 approved_reasonThis is approved
 approved_date(null)
 final_report(null)
 implication_results(null)
 quantity_imported(null)
 quantity_dispensed(null)
 quantity_destroyed(null)
 quantity_exported(null)
 balance_site(null)
 final_date(null)
 ecitizen_invoice324073
 modified2025-02-13 08:07:31
 created2025-01-22 10:39:23
 InvestigatorContact(array)
 0(array)
 id91
 application_id158
 given_nameHiroko Lewis
 middle_nameTatyana Medina
 family_nameCastor Gallagher
 qualificationQuis molestiae voluptate aut aliquam velit est consequat Asperiores possimus et neque molestias aliqua Omnis voluptas non dolor nulla laudantium
 professional_addressNisi qui dolor optio tempore quisquam laborum Suscipit
 telephone+1 (322) 766-3057
 emailtipyhuqo@mailinator.com
 created2025-01-13 12:13:08
 modified2025-02-13 08:07:31
 SiteDetail(array)
 0(array)
 id128
 application_id158
 county_id42
 site_nameMiranda Alvarez
 physical_addressAut ad quasi commodi non sint libero enim eos consequatur corrupti harum non
 contact_detailsP.O. Box 86856
 contact_personVoluptatibus molestias eligendi non repudiandae quis ipsa minim quia nostrum ut nisi possimus veniam
 site_capacity(null)
 misc(null)
 created2013-06-27 10:49:32
 modified2025-02-13 08:07:31
 County(array)
 id42
 county_nameKisumu
 created2012-06-15 10:27:02
 modified2012-06-15 10:27:02
 Sponsor(array)
 0(array)
 id39
 application_id158
 sponsorEnim sint voluptatem eos nobis reiciendis dolore et qui corrupti quod minim pariatur Possimus
 sponsor_typeLocal Kenyan Investigator
 contact_personDolorem mollitia id quis provident error voluptatem voluptate
 addressDolore laborum delectus dolor corrupti rerum aut magnam impedit quia cillum et cupiditate aliquid sapiente
 telephone_number+1 (666) 325-1183
 fax_number+1 (314) 248-5575
 cell_number+1 (134) 102-6236
 email_addresstuhokelyh@mailinator.com
 created2025-01-13 12:13:08
 modified2025-02-13 08:07:31
 4(array)
 Application(array)
 id128
 user_id29
 application_id(null)
 is_child0
 trial_status_id10
 total_sites2
 abstract_of_study\n samlpe\n
 study_title\n Jan 7th\n
 laymans_summary\n sample Laymans Summary\n
 short_titleQuis quaerat anim voluptatem p
 protocol_noECCT/25/01/02
 reference_no
 version_noOdit nulla saepe ut possimus esse maiores
 date_of_protocol02-01-2025
 study_drugSed velit rerum vel reprehenderit aut aliquid
 disease_conditionEst excepteur odio quasi aut accusantium fugiat iste ab non aut impedit minima quidem dolorum id aut aliquip dolore
 product_type_biologicals1
 product_type_proteins1
 product_type_immunologicals1
 product_type_vaccines0
 product_type_hormones1
 product_type_toxoid1
 product_type_chemical1
 product_type_medical_device1
 product_type_chemical_nameIlliana Smith
 product_type_medical_device_nameKennedy Cote
 comparatorYes
 comparator_nameMyra Anderson
 comparator_registeredVoluptas consequat Veniam ar
 comparator_countriesConsequat Voluptati
 ecct_not_applicable0
 ecct_ref_number
 email_addressjkiprotich@intellisoftkenya.com
 applicant_covering_letter1
 applicant_protocol1
 applicant_patient_information1
 applicant_investigators_brochure1
 applicant_investigators_cv1
 applicant_signed_declaration1
 applicant_financial_declaration1
 applicant_gmp_certificate1
 applicant_indemnity_cover1
 applicant_opinion_letter1
 applicant_approval_letter1
 applicant_statement1
 applicant_participating_countries(null)
 applicant_addendum1
 applicant_fees1
 applicant_complete_form(null)
 applicant_impd1
 applicant_prev_data1
 applicant_stability_data1
 applicant_analysis_cert1
 applicant_pictorial_sample1
 applicant_gcp_training1
 applicant_dsmb_charter1
 applicant_detailed_budget1
 applicant_indemnity_pi1
 applicant_practice_license1
 applicant_registration_ctr(null)
 applicant_pan_african1
 applicant_hard_copies(null)
 applicant_signed_checklist1
 statistical_analysis_plan1
 applicant_contractual_agreement1
 declaration_applicantVoluptate necessitatibus aliqua Labore ea deserunt eu amet excepturi
 declaration_date102-01-2025
 declaration_principal_investigatorSint voluptates quasi ipsum asperiores nisi quae eum deserunt quod quaerat saepe
 declaration_date203-01-2025
 placebo_presentYes
 study_objectives\n sample\n
 principal_inclusion_criteria\n sample\n
 principal_exclusion_criteria\n sample\n
 primary_end_points\n sample\n
 scope_diagnosis1
 scope_prophylaxis1
 scope_therapy1
 scope_safety0
 scope_efficacy1
 scope_pharmacokinetic1
 scope_pharmacodynamic1
 scope_bioequivalence0
 scope_dose_response0
 scope_pharmacogenetic1
 scope_pharmacogenomic1
 scope_pharmacoecomomic1
 scope_others1
 scope_others_specifyMinima proident aut
 trial_human_pharmacology1
 trial_administration_humans1
 trial_bioequivalence_study0
 trial_other0
 trial_other_specifyIn temporibus volupt
 trial_therapeutic_exploratory0
 trial_therapeutic_confirmatory0
 trial_therapeutic_use1
 design_controlledYes
 site_capacity(null)
 staff_numbers\n sample\n
 other_details_explanation\n sample\n
 other_details_regulatory_notapproved\n sample\n
 other_details_regulatory_approved\n sample\n
 other_details_regulatory_rejected\n sample\n
 other_details_regulatory_halted\n sample\n
 estimated_durationVoluptatem accusamus similique quia velit quidem ipsa mollit vitae omnis odio pariatur Voluptas et possimus illum tempora id ut maiores
 design_controlled_randomisedNo
 design_controlled_openNo
 design_controlled_single_blindNo
 design_controlled_double_blindYes
 design_controlled_parallel_groupNo
 design_controlled_cross_overYes
 design_controlled_otherYes
 design_controlled_specifyEt excepteur do velit illum blanditiis vel
 design_controlled_comparatorEst deserunt ipsa harum
 design_controlled_other_medicinalYes
 design_controlled_placeboNo
 design_controlled_medicinal_otherYes
 design_controlled_medicinal_specifyEst elit ipsa dolorem debitis atque quod mollitia exercitationem elit tempor totam alias
 single_site_member_stateNo
 location_of_area
 single_site_physical_address
 single_site_contact_person
 single_site_telephone
 multiple_sites_member_stateYes
 multiple_countriesYes
 multiple_member_states141
 number_of_sites261
 multi_country_listSint dolore earum i
 data_monitoring_committeeNo
 total_enrolment_per_siteHic et dolor placeat
 total_participants_worldwideDolor ut rem nobis perspiciatis qui necessitatibus facere modi deleniti ut rerum qui atque cupiditate enim quo tempora totam
 population_less_than_18_yearsYes
 population_uteroYes
 population_preterm_newbornYes
 population_newbornYes
 population_infant_and_toddlerNo
 population_childrenNo
 population_adolescentNo
 population_above_18Yes
 population_adultYes
 population_elderlyNo
 gender_female1
 gender_male1
 subjects_healthyYes
 subjects_patientsYes
 subjects_vulnerable_populationsYes
 subjects_women_child_bearingNo
 subjects_women_using_contraceptionNo
 subjects_pregnant_womenYes
 subjects_nursing_womenUnclear
 subjects_emergency_situationYes
 subjects_incapable_consentYes
 subjects_specifyRatione optio accus
 subjects_othersYes
 subjects_others_specifyIncididunt dolores i
 investigator1_given_nameCarissa Haley
 investigator1_middle_nameHashim Ellison
 investigator1_family_nameRuby Conway
 investigator1_qualificationCorrupti id et velit aperiam sunt eligendi do minim illum et eos tenetur autem modi non et dolore magna eius
 investigator1_professional_addressCulpa in qui rerum mollit voluptatem quisquam rerum esse dolore libero non aut inventore dicta quis voluptatem molestiae
 investigator1_telephone+1 (852) 478-7381
 investigator1_emailpinewideji@mailinator.com
 organisations_transferred_Yes
 number_participantsEx eu est et quos
 notification\n sample\n
 approval_date07-01-2025
 submitted1
 deleted0
 deleted_date(null)
 deactivated0
 date_submitted17-02-2025
 unsubmitted1
 initial_date_submitted17-02-2025
 admin_stopped0
 admin_stopped_reason(null)
 approved2
 approved_reasonSample
 approved_date(null)
 final_report\n Sample Executive\n
 implication_results\n Sample Implications of the results on current practice\n
 quantity_imported10
 quantity_dispensed13
 quantity_destroyed13
 quantity_exported12
 balance_site15
 final_date2025-07-11
 ecitizen_invoice344039
 modified2025-07-11 17:18:26
 created2025-01-07 09:26:39
 InvestigatorContact(array)
 0(array)
 id86
 application_id128
 given_nameBaker Spears
 middle_nameCassandra Castaneda
 family_nameLane Robbins
 qualificationBlanditiis consequatur recusandae Natus libero quis
 professional_addressOfficiis illo laborum cupiditate do dolores omnis in sint quisquam nostrud fuga Perspiciatis nemo
 telephone+1 (993) 659-9852
 emailpenoguje@mailinator.com
 created2025-01-07 09:33:40
 modified2025-02-17 10:51:23
 SiteDetail(array)
 0(array)
 id1706
 application_id128
 county_id43
 site_nameDaquan Lane
 physical_addressUt qui enim recusandae Unde qui esse beatae autem quia velit
 contact_detailsPO Box 5703
 contact_personVeniam optio vel modi repellendus
 site_capacity(null)
 misc(null)
 created2025-01-07 09:33:40
 modified2025-02-17 10:51:23
 County(array)
 id43
 county_nameHoma Bay
 created2012-06-15 10:27:10
 modified2012-06-15 10:27:10
 Sponsor(array)
 0(array)
 id35
 application_id128
 sponsorAut voluptatum est ab voluptas tempore aut et voluptas dolore architecto ad suscipit saepe omnis quaerat
 sponsor_typeLocal Kenyan Investigator
 contact_personQuas ut consectetur ratione est tempor quo odio iure esse occaecat eius suscipit explicabo Quasi sit
 addressExcepteur distinctio Enim vitae reiciendis aut aliquid incididunt repudiandae nesciunt beatae adipisci
 telephone_number+1 (731) 766-1698
 fax_number+1 (493) 753-7389
 cell_number+1 (179) 791-1499
 email_addresscovoginoby@mailinator.com
 created2025-01-07 09:33:40
 modified2025-02-17 10:51:23
- page_options(array)
 55
 1010
- redir
- $request->data(array)
 Application(array)
 trial_therapeutic_use1
- $this->validationErrors(array)
 Permission(empty)
 Aro(empty)
 Aco(empty)
 Application(empty)
 User(empty)
 TrialStatus(empty)
 InvestigatorContact(empty)
 Sponsor(empty)
 SiteDetail(empty)
 County(empty)
- Loaded Helpers(array)
 0Html
 1Form
 2Session
 3Text
 4Number
 5SimpleGraph
 6Paginator
 7DebugTimer
 8Toolbar
 9HtmlToolbar
====

Environment

App Constants

Constant	Value
MEDIA	'/var/www/ctr/app/webroot/media/'
MEDIA_STATIC	'/var/www/ctr/app/webroot/media/static/'
MEDIA_FILTER	'/var/www/ctr/app/webroot/media/filter/'
MEDIA_TRANSFER	'/var/www/ctr/app/webroot/media/transfer/'
MEDIA_URL	'media/'
MEDIA_STATIC_URL	'media/static/'
MEDIA_FILTER_URL	'media/filter/'
MEDIA_TRANSFER_URL	'media/transfer/'
HTTP_HOST	'45.79.161.190:8080'
HTTP_BASE	'http://45.79.161.190:8080'
HTTP_SELF	'/app/webroot/index.php'
HTTP_URI	'/applications/index/sort:protocol_no/direction:desc/page:1/trial_therapeutic_use:1'
CHOWN_PUBLIC	(int) 504
LF	''
NL	''
CR	''
TB	''
BR	' '
WINDOWS	false
FORMAT_DB_DATETIME	'Y-m-d H:i:s'
FORMAT_DB_DATE	'Y-m-d'
FORMAT_DB_TIME	'H:i:s'
DEFAULT_DATETIME	'0000-00-00 00:00:00'
DEFAULT_DATE	'0000-00-00'
DEFAULT_TIME	'00:00:00'
FILES	'/var/www/ctr/app/files/'
LOCALE	'/var/www/ctr/app/locale/'
CLASS_USER	'User'
VALID_ALPHA	'/^[a-zA-Z]+$/'
VALID_ALPHA_UNDERSCORES	'/^[a-zA-Z_]+$/'
VALID_ALPHA_MINUS_UNDERSCORES	'/^[a-zA-Z_-]+$/'
VALID_ALPHA_WHITESPACES	'/^[a-zA-Z ]+$/'
VALID_ALPHANUMERIC_UNDERSCORES	'/^[\da-zA-Z_]+$/'
VALID_ALPHANUMERIC_MINUS_UNDERSCORES	'/^[\da-zA-Z_-]+$/'
VALID_ALPHANUMERIC_WHITESPACES	'/^[\da-zA-Z ]+$/'
VALID_ALPHANUMERIC_WHITESPACES_UNDERSCORES	'/^[\da-zA-Z _]+$/'
VALID_NUMERIC_UNDERSCORES	'/^[\d_]+$/'
VALID_NUMERIC_WHITESPACES	'/^[\d ]+$/'
VALID_NUMERIC_WHITESPACES_UNDERSCORES	'/^[\d _]+$/'
VALID_INTEGERS	'/^[\d]+$/'
FORMAT_NICE_YMDHMS	'd.m.Y, H:i:s'
FORMAT_NICE_YMDHM	'd.m.Y, H:i'
FORMAT_NICE_YM	'm.Y'
FORMAT_NICE_YMD	'd.m.Y'
FORMAT_NICE_MD	'd.m.'
FORMAT_NICE_D	'd'
FORMAT_NICE_W_NUM	'w'
FORMAT_NICE_W_ABBR	'D'
FORMAT_NICE_W_FULL	'l'
FORMAT_NICE_M	'm'
FORMAT_NICE_M_ABBR	'M'
FORMAT_NICE_M_FULL	'F'
FORMAT_NICE_Y_ABBR	'y'
FORMAT_NICE_Y	'Y'
FORMAT_NICE_HM	'H:i'
FORMAT_NICE_HMS	'H:i:s'
FORMAT_LOCAL_WA_YMDHMS	'%a, %d.%m.%Y, %H:%M:%S'
FORMAT_LOCAL_WF_YMDHMS	'%A, %d.%m.%Y, %H:%M:%S'
FORMAT_LOCAL_WA_YMDHM	'%a, %d.%m.%Y, %H:%M'
FORMAT_LOCAL_WF_YMDHM	'%A, %d.%m.%Y, %H:%M'
FORMAT_LOCAL_YMDHMS	'%d.%m.%Y, %H:%M:%S'
FORMAT_LOCAL_YMDHM	'%d.%m.%Y, %H:%M'
FORMAT_LOCAL_YMD	'%d.%m.%Y'
FORMAT_LOCAL_MD	'%d.%m.'
FORMAT_LOCAL_D	'%d'
FORMAT_LOCAL_W_NUM	'%w'
FORMAT_LOCAL_W_ABBR	'%a'
FORMAT_LOCAL_W_FULL	'%A'
FORMAT_LOCAL_M	'%m'
FORMAT_LOCAL_M_ABBR	'%b'
FORMAT_LOCAL_M_FULL	'%B'
FORMAT_LOCAL_Y_ABBR	'%y'
FORMAT_LOCAL_YMS_ABBR	'%d.%m.%y'
FORMAT_LOCAL_Y	'%Y'
FORMAT_LOCAL_H	'%H'
FORMAT_LOCAL_S	'%S'
FORMAT_LOCAL_HM	'%H:%M'
FORMAT_LOCAL_HMS	'%H:%M:%S'
CHAR_LESS	'<'
CHAR_GREATER	'>'
CHAR_QUOTE	'"'
CHAR_APOSTROPHE	'''
CHAR_ARROWS	'»'
CHAR_ARROWS_R	'»'
CHAR_ARROWS_L	'«'
CHAR_AVERAGE	'Ø'
CHAR_INFIN	'∞'
CHAR_MILL	'‰'
CHAR_PLUSMN	'±'
CHAR_HELLIP	'…'
CHAR_CIRCA	'≈'
CHAR_CHECKBOX_EMPTY	'☐]'
CHAR_CHECKBOX_MAKRED	'☑'
CHAR_CHECKMARK	'✓'
CHAR_CHECKMARK_BOLD	'✔'
CHAR_BALLOT	'✗'
CHAR_BALLOT_BOLD	'✘'
CHAR_ABOUT	'≈'
CHAR_RPIME	'′'
CHAR_DOUBLE_RPIME	'″'

CakePHP Constants

Constant	Value
APP	'/var/www/ctr/app/'
APP_DIR	'app'
APPLIBS	'/var/www/ctr/app/Lib/'
CACHE	'/var/www/ctr/app/tmp/cache/'
CAKE	'/var/www/ctr/lib/Cake/'
CAKE_CORE_INCLUDE_PATH	'/var/www/ctr/lib'
CORE_PATH	'/var/www/ctr/lib/'
CAKE_VERSION	'2.2.2'
CSS	'/var/www/ctr/app/webroot/css/'
CSS_URL	'css/'
DS	'/'
FULL_BASE_URL	'http://45.79.161.190:8080'
IMAGES	'/var/www/ctr/app/webroot/img/'
IMAGES_URL	'img/'
JS	'/var/www/ctr/app/webroot/js/'
JS_URL	'js/'
LOGS	'/var/www/ctr/app/tmp/logs/'
ROOT	'/var/www/ctr'
TESTS	'/var/www/ctr/app/Test/'
TMP	'/var/www/ctr/app/tmp/'
VENDORS	'/var/www/ctr/vendors/'
WEBROOT_DIR	'webroot'
WWW_ROOT	'/var/www/ctr/app/webroot/'

PHP Environment

Environment Variable	Value
Php Version	'5.6.40-63+ubuntu18.04.1+deb.sury.org+2'
Redirect Redirect Status	'200'
Redirect Status	'200'
Http Accept	'/'
Http User Agent	'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)'
Http Accept Encoding	'gzip, br, zstd, deflate'
Http Host	'45.79.161.190:8080'
Http Via	'1.1 squid-proxy-5b5d847c96-qq957 (squid/6.10)'
Http X Forwarded For	'10.3.82.253'
Http Cache Control	'max-age=259200'
Http Connection	'keep-alive'
Path	'/usr/local/sbin:/usr/local/bin:/usr/sbin:/usr/bin:/sbin:/bin:/snap/bin'
Server Signature	' Apache/2.4.29 (Ubuntu) Server at 45.79.161.190 Port 8080 '
Server Software	'Apache/2.4.29 (Ubuntu)'
Server Name	'45.79.161.190'
Server Addr	'45.79.161.190'
Server Port	'8080'
Remote Addr	'216.73.216.36'
Document Root	'/var/www/ctr'
Request Scheme	'http'
Context Prefix	''
Context Document Root	'/var/www/ctr'
Server Admin	'webmaster@localhost'
Script Filename	'/var/www/ctr/app/webroot/index.php'
Remote Port	'23720'
Redirect Url	'/app/webroot/applications/index/sort:protocol_no/direction:desc/page:1/trial_therapeutic_use:1'
Gateway Interface	'CGI/1.1'
Server Protocol	'HTTP/1.1'
Request Method	'GET'
Query String	''
Request Uri	'/applications/index/sort:protocol_no/direction:desc/page:1/trial_therapeutic_use:1'
Script Name	'/app/webroot/index.php'
Php Self	'/app/webroot/index.php'
Request Time Float	(float) 1756487709.6
Request Time	(int) 1756487709

====

Include
+
Included Files

Include Paths
- 0/var/www/ctr/app/Plugin/Media/Lib/mm/src
- 1/var/www/ctr/lib
- 3/usr/share/php
- 4-> /var/www/ctr/lib/Cake/
Included Files
- core(array)
  Behavior(array)
  0CORE/Model/Behavior/TreeBehavior.php
  1CORE/Model/Behavior/ContainableBehavior.php
  2CORE/Model/Behavior/AclBehavior.php
  Cache(array)
  0CORE/Cache/Cache.php
  1CORE/Cache/Engine/FileEngine.php
  2CORE/Cache/CacheEngine.php
  Component(array)
  0CORE/Controller/Component/AclComponent.php
  1CORE/Controller/Component/Acl/DbAcl.php
  2CORE/Controller/Component/Acl/AclInterface.php
  3CORE/Controller/Component/AuthComponent.php
  4CORE/Controller/Component/RequestHandlerComponent.php
  5CORE/Controller/Component/SessionComponent.php
  6CORE/Controller/Component/PaginatorComponent.php
  Config(array)
  0CORE/Config/routes.php
  1CORE/Config/config.php
  Controller(array)
  0CORE/Controller/Controller.php
  1CORE/Controller/ComponentCollection.php
  2CORE/Controller/Component.php
  Datasource(array)
  0CORE/Model/Datasource/CakeSession.php
  1CORE/Model/Datasource/Database/Mysql.php
  2CORE/Model/Datasource/DboSource.php
  3CORE/Model/Datasource/DataSource.php
  Error(array)
  0CORE/Error/exceptions.php
  1CORE/Error/ErrorHandler.php
  I18n(array)
  0CORE/I18n/I18n.php
  1CORE/I18n/L10n.php
  Log(array)
  0CORE/Log/CakeLog.php
  1CORE/Log/LogEngineCollection.php
  2CORE/Log/Engine/FileLog.php
  3CORE/Log/Engine/BaseLog.php
  4CORE/Log/CakeLogInterface.php
  Model(array)
  0CORE/Model/ConnectionManager.php
  1CORE/Model/Permission.php
  2CORE/Model/Model.php
  3CORE/Model/BehaviorCollection.php
  4CORE/Model/Aro.php
  5CORE/Model/AclNode.php
  6CORE/Model/Aco.php
  7CORE/Model/ModelBehavior.php
  Network(array)
  0CORE/Network/CakeRequest.php
  1CORE/Network/CakeResponse.php
  Other(array)
  0CORE/bootstrap.php
  1CORE/basics.php
  2CORE/Core/App.php
  3CORE/Core/Configure.php
  4CORE/Core/CakePlugin.php
  5CORE/Event/CakeEventListener.php
  6CORE/Event/CakeEvent.php
  7CORE/Event/CakeEventManager.php
  8CORE/Core/Object.php
  Routing(array)
  0CORE/Routing/Dispatcher.php
  1CORE/Routing/Filter/AssetDispatcher.php
  2CORE/Routing/DispatcherFilter.php
  3CORE/Routing/Filter/CacheDispatcher.php
  4CORE/Routing/Router.php
  5CORE/Routing/Route/CakeRoute.php
  6CORE/Routing/Route/PluginShortRoute.php
  Utility(array)
  0CORE/Utility/Hash.php
  1CORE/Utility/Inflector.php
  2CORE/Utility/ObjectCollection.php
  3CORE/Utility/Debugger.php
  4CORE/Utility/String.php
  5CORE/Utility/ClassRegistry.php
  6CORE/Utility/Set.php
  7CORE/Utility/Sanitize.php
  View(array)
  0CORE/View/HelperCollection.php
- app(array)
  Behavior(array)
  0APP/Model/Behavior/SoftDeleteBehavior.php
  Config(array)
  0APP/Config/core.php
  1APP/Config/bootstrap.php
  2APP/Config/routes.php
  3APP/Config/database.php
  Controller(array)
  0APP/Controller/ApplicationsController.php
  1APP/Controller/AppController.php
  Model(array)
  0APP/Model/AppModel.php
  1APP/Model/Application.php
  2APP/Model/User.php
  3APP/Model/TrialStatus.php
  4APP/Model/InvestigatorContact.php
  5APP/Model/Sponsor.php
  6APP/Model/SiteDetail.php
  7APP/Model/County.php
  Other(array)
  0APP/webroot/index.php
- plugins(array)
  CakePdf(array)
  Config(array)
  0CakePdf/Config/bootstrap.php
  1CakePdf/Config/routes.php
  CakeResque(array)
  Config(array)
  0CakeResque/Config/bootstrap.php
  Plugin(array)
  0CakeResque/Lib/CakeResque.php
  1CakeResque/vendor/kamisama/php-resque-ex/lib/Resque.php
  2CakeResque/vendor/kamisama/php-resque-ex/lib/Resque/Event.php
  3CakeResque/vendor/kamisama/php-resque-ex/lib/Resque/Exception.php
  DebugKit(array)
  Component(array)
  0DebugKit/Controller/Component/ToolbarComponent.php
  Plugin(array)
  0DebugKit/Lib/DebugMemory.php
  1DebugKit/Lib/Panel/HistoryPanel.php
  2DebugKit/Lib/DebugPanel.php
  3DebugKit/Lib/Panel/SessionPanel.php
  4DebugKit/Lib/Panel/RequestPanel.php
  5DebugKit/Lib/Panel/SqlLogPanel.php
  6DebugKit/Lib/Panel/TimerPanel.php
  7DebugKit/Lib/Panel/LogPanel.php
  8DebugKit/Lib/Log/Engine/DebugKitLog.php
  9DebugKit/Lib/Panel/VariablesPanel.php
  10DebugKit/Lib/Panel/EnvironmentPanel.php
  11DebugKit/Lib/Panel/IncludePanel.php
  12DebugKit/Lib/DebugTimer.php
  Media(array)
  Config(array)
  0Media/Config/bootstrap.php
  Plugin(array)
  0Media/Lib/mm/src/Mime/Type.php
  1Media/Lib/mm/src/Mime/Type/Magic/Adapter/Fileinfo.php
  2Media/Lib/mm/src/Mime/Type/Magic/Adapter.php
  3Media/Lib/mm/src/Mime/Type/Glob/Adapter/Memory.php
  4Media/Lib/mm/src/Mime/Type/Glob/Adapter.php
  5Media/Lib/mm/src/Media/Process.php
  6Media/Lib/mm/src/Media/Info.php
  Search(array)
  Component(array)
  0Search/Controller/Component/PrgComponent.php
  Behavior(array)
  0Search/Model/Behavior/SearchableBehavior.php
  Shim(array)
  Config(array)
  0Shim/Config/bootstrap.php
  Tools(array)
  Config(array)
  0Tools/Config/bootstrap.php
====

Clinical Trial Applications: Filter, Search, and view applications {lang: 'en-GB'}

Request History

Session

Request

Cake Params

Post data

Query string

Cookie

Current Route

Sql Logs

default

Total Time: 2 ms Total Queries: 11 queries

Query Explain:

Memory

Timers

Logs

View Variables

App Constants

CakePHP Constants

PHP Environment

Included Files

Include Paths

Included Files

Clinical Trial Applications: Filter, Search, and view applications

Total Time: 2 ms
Total Queries: 11 queries